The use of SBRT was less likely than conventional fractionation in patients with a higher Gleason score (AOR for >7 vs <7, 0.09 [95% CI, 0.08-0.09]; P < .001), higher PSA level (AOR for >20 vs ≤4 ng/mL, 0.41 [95% CI, 0.37-0.45]; P < .001), and higher tumor grade (AOR for T3a-T3b vs T1a-T2a, 0.21 [95% CI, 0.17-0.25]; P < .001). This evidence concerns the gene KLK3 and neoplasm.